{"id":27907,"date":"2014-08-11T11:46:12","date_gmt":"2014-08-11T15:46:12","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=27907"},"modified":"2014-08-11T11:46:12","modified_gmt":"2014-08-11T15:46:12","slug":"clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907","title":{"rendered":"Clovis Oncology Inc (NASDAQ:CLVS) Going Strong With The Clinical Developmental Programs"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/11\/2014 (wallstreetpr) \u2013<b> Clovis Oncology Inc (NASDAQ:CLVS)<\/b> posted second quarter financial results and gave the necessary information on its clinical <a href=\"http:\/\/www.marketwatch.com\/story\/clovis-oncology-announces-second-quarter-2014-operating-results-2014-08-07\" target=\"_blank\">developmental<\/a> programs for the year. It said that the CO-1686 NDA submission is expected by mid-2015. President and CEO, Patrick J. Mahaffy said that the company is going through an exciting time. It is enrolling patients in the CO-1686 Phase 2 expansion and TIGER2 studies. It is building on the medical affairs and commercial relationships as it expects the launch to materialize by year-end 2015. He also talked about the results of rucaparib ARIEL2 study. The study results are encouraging and Clovis Oncology Inc (NASDAQ:CLVS) can present the data of its development programs in the future scientific meetings.<\/p>\n<p style=\"text-align: justify;\"><b>The Financial Results<\/b><\/p>\n<p style=\"text-align: justify;\">Clovis Oncology Inc (NASDAQ:CLVS) stocks climbed by more than 10% after the second-quarter financial results. It reported the net loss at $34.8 million as compared to $19.3 million in the 2Q2013. The net loss came at $1.03 per share comparable to $0.72 per share in the 2Q2013. Clovis reported the R&amp;D expenses of $28.4 million as compared to $15.8 million in the 2Q2013. The R&amp;D expenses for the first half of fiscal year stands at $52.6 million as compared to $27.9 million in first half of year 2013.<\/p>\n<p style=\"text-align: justify;\"><b>Higher R&amp;D Expenses<\/b><\/p>\n<p style=\"text-align: justify;\">The higher R&amp;D expenses can be attributed to the initiation expenses of the ARIEL3 and ARIEL2 studies for rucaparib. The initiation of the TIGER2 study and the Japanese Phase 1 studies for rociletinib added to the research and development expenses. The other reasons are higher personnel-related expenses to get the supporting staff for development activities and the increased manufacturing costs of clinical drug supplies for the rucaparib and the rociletinib programs. The G&amp;A expenses came at $5.3 million as compared to $3.5 million in the 2Q2013. The operating expenses came at $35.0 million including the acquired in-process R&amp;D expenses.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/11\/2014 (wallstreetpr) \u2013 Clovis Oncology Inc (NASDAQ:CLVS) posted second quarter financial results and gave the necessary information on its clinical developmental programs for [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":27908,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[7801,2436,2437,7805],"stock_ticker":[],"class_list":["post-27907","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-clovis-oncology-inc","tag-clovis-oncology-inc-nasdaqclvs","tag-nasdaqclvs","tag-patrick-j-mahaffy","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Clovis Oncology Inc (NASDAQ:CLVS) Going Strong With The Clinical Developmental Programs - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clovis Oncology Inc (NASDAQ:CLVS) Going Strong With The Clinical Developmental Programs - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/11\/2014 (wallstreetpr) \u2013 Clovis Oncology Inc (NASDAQ:CLVS) posted second quarter financial results and gave the necessary information on its clinical developmental programs for [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-11T15:46:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/images4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"350\" \/>\n\t<meta property=\"og:image:height\" content=\"144\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Clovis Oncology Inc (NASDAQ:CLVS) Going Strong With The Clinical Developmental Programs\",\"datePublished\":\"2014-08-11T15:46:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907\"},\"wordCount\":322,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/images4.jpg\",\"keywords\":[\"Clovis Oncology Inc\",\"Clovis Oncology Inc (NASDAQ:CLVS)\",\"NASDAQ:CLVS\",\"Patrick J. Mahaffy\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907\",\"name\":\"Clovis Oncology Inc (NASDAQ:CLVS) Going Strong With The Clinical Developmental Programs - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/images4.jpg\",\"datePublished\":\"2014-08-11T15:46:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/images4.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/images4.jpg\",\"width\":350,\"height\":144},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clovis Oncology Inc (NASDAQ:CLVS) Going Strong With The Clinical Developmental Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clovis Oncology Inc (NASDAQ:CLVS) Going Strong With The Clinical Developmental Programs - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907","og_locale":"en_US","og_type":"article","og_title":"Clovis Oncology Inc (NASDAQ:CLVS) Going Strong With The Clinical Developmental Programs - Wall Street PR","og_description":"Boston, MA 08\/11\/2014 (wallstreetpr) \u2013 Clovis Oncology Inc (NASDAQ:CLVS) posted second quarter financial results and gave the necessary information on its clinical developmental programs for [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-11T15:46:12+00:00","og_image":[{"width":350,"height":144,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/images4.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Clovis Oncology Inc (NASDAQ:CLVS) Going Strong With The Clinical Developmental Programs","datePublished":"2014-08-11T15:46:12+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907"},"wordCount":322,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/images4.jpg","keywords":["Clovis Oncology Inc","Clovis Oncology Inc (NASDAQ:CLVS)","NASDAQ:CLVS","Patrick J. Mahaffy"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907","url":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907","name":"Clovis Oncology Inc (NASDAQ:CLVS) Going Strong With The Clinical Developmental Programs - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/images4.jpg","datePublished":"2014-08-11T15:46:12+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/images4.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/images4.jpg","width":350,"height":144},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-going-strong-with-the-clinical-developmental-programs-27907#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Clovis Oncology Inc (NASDAQ:CLVS) Going Strong With The Clinical Developmental Programs"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/27907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=27907"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/27907\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/27908"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=27907"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=27907"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=27907"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=27907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}